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Abstract
Anthracyclines drugs are used as a treatment regime to combat cancer owing to 
their great chemotherapeutic potential. They are characterized by the presence of 
a wide range of derivatives, the most famous are doxorubicin and daunorubicin. 
The proposed action mechanism of anthracyclines and their derivatives to exert 
cytotoxic effect involves the intercalation of the drug molecule into nucleic acid and 
inhibition of the activity of topoisomerases. These events consequences in halting 
DNA replication and transcription mechanisms of the cell. Understanding of the 
structural and conformational changes associated with nucleic acid after binding 
with drugs provides significant knowledge for the development of more effective 
drugs. A comprehensive elucidation of the molecular mechanism(s) of action of 
anthracyclines drugs plays a significant role in the rational drug designing to obtain 
an effective, selective, and safe anti-cancer drugs.
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1. Introduction
Anthracyclines were primarily recognized as antibiotics due to their anti-
bacterial properties in 1939 [1]. However, the chemical characterization of the 
anthracyclines which includes a rigid planar aromatic ring that remains bound to 
an amino-sugar by a glycosidic bond (Figures 1 and 2). Quinone and hydroquinone 
groups of these molecules on adjacent rings allow gain and loss of electrons in the 
conversion of quinone to the semiquinone radical [2, 3]. This semiquinone free 
radical converts back to quinine under aerobic conditions resulting in the formation 
of superoxide anion and hydrogen peroxide. The excessive formation of these free 
radical consequences in lipid peroxidation within cell membranes, DNA damage 
and finally cell death. This makes them the potent non-selective anti-cancer drugs 
i.e., they are used in the treatment of a wide range of cancer like small cell lung 
cancer, breast cancer, lymphoblastic and myeloblastic leukemia, etc. [1, 4–6]. There 
is a high probability that a cancer patient will be administered with anthracycline 
at some stage of their chemotherapy session. Daunomycin and doxorubicin were 
the earliest anthracyclines isolated from Streptomyces peucetius and were effective 
against a wide range of human cancers. Owing to significant antitumor potential, 
the World Health Organization (WHO) has included daunomycin and doxorubicin 
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in the model list of medicines [7]. But it has been discovered that repeated admin-
istration of these drugs can impart chemotherapy-resistance to the tumors and 
cardiotoxicity [4]. To reduce or subside these side effects, major efforts are being 
done to find better alternatives. Therefore, the study of more than 2000 analogs has 
been done so far [8].
Regarding the chemical structure of daunomycin C27H29NO10 and doxorubicin 
C27H29NO11, they share the same carbon skeleton (Figure 1). The difference in their 
chemical structure comes at the side chain at C-14 position; daunomycin has a 
hydrogen atom whereas doxorubicin has an alcohol group (Figure 1) [5, 6].
2. Proposed action mechanisms
2.1 Anthracyclines as DNA intercalators
The exact mechanism of the anthracycline in the body is not known and still 
under investigation. However, DNA is recognized as the prime target of well-known 
anthracycline like doxorubicin. The primary mechanism involves the intercala-
tion of planar tetracyclic chromophore between the DNA base pairs subsequently 
affecting the transcription and translation of DNA. The binding affinity of the drug 
to DNA is not only the factor contributing to the cytotoxic activity of anthracyclines 
but other factors like binding mode and binding site of anthracycline also play 
important role in exerting cytotoxic effects.
Figure 1. 
Chemical structure of doxorubicin and daunorubicin. Dotted circle and dotted line arrow represents probable 
substitution position in anthracyclines. Doxorubicin and daunorubicin differ at C14 position encircled with 2. 
Green dotted line is used to depict aglycone and sugar moieties of anthracycline drugs. Chemical structures were 
rendered using ChemDeaw software.
Figure 2. 
Chemical structure of epirubicin and idarubicin. Epirubicin and doxorubicin (Figure 1) differs at position 
no. 3 (C4′ of sugar moiety, stereoisomer). Idarubicin differs from daunorubicin (Figure 1) at position 1 by 
absence of methoxy group. Chemical structures were rendered using ChemDraw software.
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The specificity, binding affinity, and the binding mode of every anthracycline 
differ with the difference in the sequence of DNA bases (Figures 3–5). Structural, 
computational and solution studies on the daunomycin-DNA complex have 
provided the information that daunomycin has preferential binding where AT is 
present between two GC base pairs i.e. GCATGC [9, 10]. Equilibrium binding and 
DNase footprinting methods were utilized to study site and sequence specificity  
of daunorubicin to DNA. The results of these experiments demonstrate that 
daunomycin indeed recognizes specific DNA sequences and its binding affinity 
with DNA increases with an increase in GC content [11]. Moreover, the effect 
of daunorubicin in cleaving the linear pBR322 DNA by restriction endonuclease 
EcoRI and PvuI was investigated to assess the sequence-specific binding of dauno-
rubicin [11]. The recognition sequence of EcoRI and PvuI are 5′-GAATTC-3′and 
5′-CGATCG-3′ respectively. Chaires et al. observed that PvuI inhibits the rate of 
digestion of pBR322 DNA more than the EcoRI suggesting preferential sequence 
specificity of daunorubicin. Similar results were evident from the crystal structure 
analysis of daunomycin-DNA d (CpGpTpApCpG) complexes (Figure 4) [10]. The 
specificity for the GC base pair is due to the hydrogen bonds formed during the 
interaction. The hydroxyl group on C9 of daunorubicin interact with N2 and N3 of 
guanine with two hydrogen bonds. This preference to GC base pair also explains 
the increase in binding affinity of the drug with an increase in GC content of DNA 
[10]. Similarly, crystal structures of anthracyclines like doxorubicin, epirubicin, 
and idarubicin show sequence-specific intercalative binding mode between DNA 
bases (Figures 3 and 5).
Moreover, several experiments were done to study the intercalation mechanism 
of anthracyclines with DNA. A spectrofluorometric method was also developed 
for the estimation of anthracycline intercalation in living cells and DNA solutions 
[12]. Belloc et al. have done measurement of anthracyclines (daunorubicin and 
idarubicin) intercalation in the DNA of living cells by flow cytometry [13]. Ashley 
et al. has demonstrated the intercalative property of anthracyclines in nuclear as 
well as in mitochondrial DNA using picogreen (fluorescent DNA binding dye) [14]. 
The intercalation of anthracycline into mitochondrial DNA has a significant impact 
Figure 3. 
Intercalation of doxorubicin between GC basepairs. Crystal structure of doxorubicin getting intercalated 
between GC bases. Structures are taken from protein data bank. Light green color depicts AT baseparing 
and dark green color shows GC bases. Red dots represent crystallized water molecules. Figure clearly depicts 
intercalation of doxorubicin in GC bases of DNA and preferential binding with nucleotide sequences.
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on mitochondrial toxicity. The effect of doxorubicin binding on the morphology of 
the single stranded DNA was further quantitatively analyzed using Atomic Force 
Microscopy (AFM). AFM studies strengthen the probable mechanism of intercala-
tive binding mode as consequences of doxorubicin interaction with DNA [15].
Other studies found that B-DNA is preferred over Z-DNA by the daunorubicin 
for binding. Allosteric conversion of the Z form into B form has also been observed 
in some cases. Ionic concentration in which usually Z form of DNA is present 
changes to B form on the binding of daunorubicin to poly dGdC or resist to change 
from B form to Z form [16]. There are several pieces of evidence suggesting drug 
binding to DNA results in the inhibition of specific DNA function contributing 
towards their therapeutic effects.
Figure 5. 
Intercalation of epirubicin and idarubicin between GC basepairs. Crystal structure of epirubicin getting 
intercalated between AT and GC basepairs. Crystal structure of idarubicin getting intercalated between GC 
bases. Structures are taken from protein data bank. Red dots represent crystallized water molecules. Figure 
clearly depicts intercalation of epirubicin and idarubicin in GC bases of DNA and preferential binding with 
nucleotide sequences.
Figure 4. 
Intercalation of daunorubicin between GC basepairs. Crystal structure of daunorubicin getting 
intercalated between GC bases. Structures are taken from protein data bank. Light green color depicts AT 
baseparing and dark green color shows GC bases. Red dots represent crystallized water molecules. Figure 
clearly depicts intercalation of doxorubicin in GC bases of DNA and preferential binding with nucleotide 
sequences.
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2.2 How anthracyclines damage DNA?
Anthracyclines are known to damage DNA by several mechanisms which include 
topoisomerase-II poisoning, free radical formation, and DNA-anthracycline adduct 
formation. The semiquinone radical of anthracycline can intercalate between DNA 
base pair resulting in DNA damage by forming reactive oxygen species (ROS).
2.2.1 Via topoisomerase II poisoning
Along with DNA intercalation, topoisomerase II is also considered as the pri-
mary target of anthracyclines [17]. Topoisomerases help in solving the topological 
problems like supercoiling, knotting, and catenation of DNA during replication, 
transcription, and recombination by creating single and double stranded breaks 
and subsequently rejoining the breaks. Based on structure and function, mam-
malian cells have two types of topoisomerases which are topoisomerase I and II. 
Topoisomerase I is monomeric and forms single strand breaks in DNA whereas 
topoisomerase II is dimeric and introduces double stranded breaks in DNA. 
Anthracyclines interfere with the normal functioning of breaking and rejoining 
of DNA strands by topoisomerases, particularly topoisomerase II consequence in 
the formation of an abortive anthracycline- DNA-topoisomerase ternary complex, 
hence poisoning the enzyme action. This ternary complex impends the religation of 
breaks in the dsDNA. Hence, anthracyclines act on topoisomerase II and stabilize 
the DNA-topoisomerase II complex. Due to this topoisomerase II which otherwise is 
essential for the normal functioning of the cell now acts as a lethal toxin to the cell 
and leads the cell to apoptosis. During intercalation, the planar ring of the aglycone 
and sugar moiety remains in contact with DNA bases while the A ring and the sub-
stituents present the C9 which are present in the minor groove of DNA interact with 
the enzyme (Figures 1 and 2). Perhaps that’s why modifying the C9 substituent 
changes the activity of the drug. Cleavage does not occur on all the sites recognized 
by the Topoisomerase II and depends on the specific base sequence where the drug 
interacts with the enzyme. An increase in drug activity is seen when the 4-methoxy 
group is removed and the sugar moiety is substituted on 3′. 3′ substitution also has 
a significant role in the determination of specific sites for anthracycline associated 
cleavage of DNA.
Several lines of evidence have shown that these anthracyclines induce irreversible 
DNA damage by forming a ternary complex with DNA topoisomerase which intro-
duces permanent double stranded breaks which ultimately lead to apoptosis in rapidly 
dividing cells [18, 19].
2.2.2 Via oxidative stress
Anthracyclines also causes the production of free radicals inside the cell which 
are responsible for the cytotoxic effect of these drugs. Though the mechanism of 
this process is still unclear increased number of reactive oxygen species (ROS) 
and the presence of deoxyaglycone in the urine after the administration of drugs 
indicates the possibility of this mechanism [5]. Oxidative stress is the imbalance 
between the reactive nitrogen species and reactive oxygen species in the cell. 
Mitochondria are believed to take part in this process. Quinone ring of the anthra-
cyline aglycone act as electron acceptor (Figures 1 and 2). In the electron transport 
chain (ETC), one electron is transferred from NADPH to flavoprotein and then to 
the aglycone due to which quinone gets reduced to form semiquinone free radical. 
This reaction is catalyzed by NADPH cytochrome P-450 reductase [20]. From 
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the semiquinone, this electron gets transferred to oxygen and semiquinone gets 
converted into stable hydroquinone in this redox cycle. Due to this electron transfer 
oxygen gets reduced to superoxide which readily gets converted to other reactive 
oxygen species like hydroxyl radical which is harmful to cells. These reactive oxygen 
species can lead to DNA damage and lipid peroxidation which finally result in cell 
apoptosis.
When oxygen becomes limiting, semiquinone free radical transfer the electron 
to other electron acceptors, and rearrangement in anthracyclines takes place. The 
aglycone ring remains connected to sugar moiety by a glycosidic bond which is 
an ether containing linkage with oxygen in it which accepts the unpaired electron 
and due to this cleavage of glycosidic bond takes place. As a result, the formation 
of 7-deoxyaglycone takes place which either directly passes through urine or as 
conjugates in the bile [5]. There are several hypotheses explaining why superoxide 
dismutase (SOD), catalase, and antioxidants do not work effectively after the 
administration of anthracyclines. Studies have shown that anthracyclines can 
alter the glutathione (GSH) level and the enzymes involved in its redox pathway. 
According to another hypothesis free radicals are formed on the cell surface or 
internally in the cell and then get transferred to the cell surface due to which SOD 
and catalase fail to act upon these ROS [17].
2.2.3 Via forming DNA-anthracycline adduct
Formation of the anthracycline-DNA adduct in the presence of formaldehyde is 
another proposed mechanism of anthracycline action. There are studies that show 
the formation of doxorubicin-DNA at clinically relevant concentrations of drugs 
[21]. Anthracycline forms covalent bond with one DNA strand and hydrogen bond 
with other DNA strand resulting in DNA damage. The reaction between anthracy-
cline and cellular formaldehyde is the foremost step to form activated Schiff base 
which then forms aminal linkage with the exocyclic amino group of guanosine. 
Formaldehyde in the cells is derived from the various carbon sources like lipids and 
spermine by iron mediated free radical reactions. In addition, Kato et al. have found 
increased formaldehyde levels in the cancer cells as compared to normal cells [22].
Phillips et al. using the bidirectional transcription footprinting technique dem-
onstrate that adriamycin-DNA adduct formation induces transcription inhibition 
with alkylation at specific DNA sites [23]. However, Bilardi et al. have demonstrated 
that anthracycline-DNA adduct induces breaks in DNA via a mechanism indepen-
dent of topoisomerase-II [24]. Moreover, DNA breaks formation occurs mainly 
due to the stalled or collapsed replication fork and these DNA breaks are repaired 
by homologous recombination dependent process. Forrest et al. investigated the 
activation of DNA damage response pathways after doxorubicin-DNA adduct 
formation and found that the downstream processing is dependent on various 
stages like recognition of adduct during replication, transcription, or any other 
stage of the cell cycle. Ataxia telangiectasia mutated (ATM) and ATM and Rad3 
related protein kinase (ATR) are the DNA damage recognition proteins that get 
activated in response to double and single DNA strand breaks respectively. Forrest 
et al. demonstrate that both ATM and ATR proteins have the capability to react with 
intermediates produced as a result of doxorubicin-DNA adduct formation [25].
DNA-anthracycline adduct formation probably follows a similar pattern as 
followed by cisplatin-DNA adduct (Figure 6). The same process also takes place 
in presence of xanthine oxidase which is present in the living cells [23, 26]. Other 
studies revealed that formaldehyde is also an important factor for the DNA adduct 
formation which is formed in the reaction media due to oxidation of different 
components in media by hydrogen peroxide. Formaldehyde has the carbon through 
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which N-C-N i.e. covalent bond forms between 3′ NH2 of amino sugar of doxoru-
bicin/daunorubicin and 2-NH2 of guanosine residue of DNA backbone (Figure 6) 
[25]. Quinone methide 1 is present as a transient form in this reaction. Further, it 
is stabilized by the hydrogen bond formed between two strands of double helical 
DNA. Though the structure of the adduct is known but the mechanism by which it 
promotes cell death is not clear [27].
Doxorubicin forms DNA adduct with the assistance of formaldehyde and the 
concentration of formaldehyde in the cell is low. So, to overcome this, some pro-
drugs are administered which gets converted to formaldehyde inside the cell for e.g. 
pivaloyloxymethyl butyrate give rise to formaldehyde inside the cell when cleaved 
by esterase. Due to DNA-anthracycline adduct formation cytotoxicity of anthracy-
clines readily increases [21].
3. Side effects
Cardiotoxicity is one of the main side effects caused by anthracyclines. Types 
of cardiotoxicity are Type I and Type II, Type I cardiotoxicity results irreversible 
cell death, while Type II cause reversible damage. At the beginning, cardiotoxicity 
thought to directly correlate with the cumulative drug dose, but later on, it was 
discovered that cardiotoxicity can occur even during the treatment [28, 29].
Increased ROS level in cardiac cells is considered as one of the factors contributing 
to anthracycline mediated cardiotoxicity. Administration of anthracyclines conse-
quences in increased ROS involving the transfer of an electron to oxygen during the 
reduction of quinone to semiquinone which further gets converted to hydroquinone 
to complete the redox cycle. This process takes place in mitochondria and the number 
of mitochondria is mostly higher in cardiomyocytes as compared to other cells [30]. 
Moreover, enzymes such as SOD, catalase, glutathione transferase, and cytochrome 
P450 which can reduce the level of ROS in cells are comparatively less in cardiomyo-
cytes resulting in an increased cardiotoxic effect [31]. According to some reports, 
doxorubicin also increases NADPH oxidase level and enzymes containing flavin like 
nitric oxide synthase, p450 reductase in cardiomyocytes. These enzymes increase the 
level of reactive oxygen species in the cell which leads to oxidative stress [31, 32].
Figure 6. 
DNA-drug adduct formation. DNA cisplatin structure was visualized and rendered using Chimera software. 
Chemical structures were rendered using ChemDraw software. (a) DNA-cisplatin adduct (PDB ID: 2NPW). 
(b) Schematic representation of doxorubicin-DNA adduct.
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Doxorubicin has a strong affinity for Fe+3 ions and the reaction of ferric ions 
with hydroxyl and ketone groups of doxorubicin results in a free radical complex 
of doxorubicin-Fe+2 [33]. The interaction between the negatively charged cell 
membranes and as this positively charged doxorubicin-Fe complex consequences 
in lipid peroxidation [33, 34]. Normally the level of iron is quite low in cells and 
usually, at this low level, doxorubicin cannot interact with iron [29]. The balance 
of iron is maintained by some transport proteins in the cell and according to some 
recent studies, doxorubicin disturbs this balance and as a result accumulation of 
iron occurs in mitochondria [34, 35]. Doxorubicin also interacts with the Fe/S 
group of iron regulatory protein IRP1 and affects its post-translational modifica-
tion due to which function of IRP1 is affected and its binding affinity to IRE (iron 
response element) becomes low resulting in an increased amount of iron in the 
cell [33]. Mitoferrin, a mitochondrial carrier protein that helps in the entry of iron 
into the mitochondria and another transfer protein mABC1 export out the iron 
from mitochondria. Doxorubicin affects the functioning of mABC1 protein due to 
which it stops the export of iron out of the mitochondria while mitoferrin functions 
normally and as a result amount of free iron increases inside mitochondria [36].
4. Anthracycline resistance
Along with cardiotoxicity, anthracyclines treatment also induce anthracycline 
resistance even at the desired cumulative dose [37]. Resistance to drugs can be either 
natural or can be acquired. Natural resistance is detected in some cells even before 
the administration of the drug. While the acquired one occurs after the administra-
tion of the drug. Several mechanics of drug resistance responsible for the incidence 
of drug-resistance which are: change in ATP- binding cassette [ABC] related drug 
efflux and accumulation, qualitative and quantitative changes in topoisomerase II, 
p53 activity, overexpression of ROS scavenging enzymes, etc. ABC (ATP- binding 
cassette) transporter proteins are considered as the primary cause of anthracycline 
related drug resistance [R]. P-glycoprotein (Pgp) is one of the ABC proteins believed 
to induce anthracycline resistance by drug efflux, inhibition of influx, and drug 
accumulation inside the cell [38]. Anthracycline interacts with Pgp which causes 
the active efflux of anthracycline from the cell through its transmembrane domain. 
Pgp is encoded by the mdr1 gene which becomes active in case of cell differentiation 
under any chemical or environmental effect. As the anthracycline interacts with the 
plasma membrane, Pgp recognizes it and exports it out. So, the increased level of 
Pgp creates an imbalance between the export and import of the drug.
Moreover, alteration in topoisomerase II activity either quantitative i.e. decrease 
in the number of enzyme or qualitative i.e. alteration in the normal activity of 
enzyme due to mutation or other reason can give resistance to cell against further 
doses of anthracyclines. Anthracycline mediated cell apoptosis also depends on 
the expression of p53. So, inactivation or down regulation of p53 can give rise to 
drug resistance [38]. SOD, GSH, catalase are the scavengers of ROS and their over 
expression can also impart anthracycline resistance during cytotoxicity [39]. An 
increase in the repair of the DNA damage caused by anthracyclines also contributes 
towards anthracyclines resistance in cells.
5. Anthracycline analogs
Several studies were conducted to understand the effect of structural changes 
in anthracyclines on their antitumor efficacy. Modification of anthracyclines has 
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a significant impact on their antitumor activity as well as on their side effects. 
Therefore, a comprehensive study on understanding the effect of specific structural 
modifications in anthracyclines to its antitumor potential and efficacy leads to the 
development of better analogs. Subtle modifications in the chemical structure of 
anthracyclines had a significant impact on the rate of drug penetration into the 
nucleus [40]. Doxorubicin and it semisynthetic analog epirubicin prepared by 
epimerization at C-4′ sugar display different antitumor potential (Figures 1 and 2). 
Moreover, epirubicin causes less cardiac damage as compared to its parent com-
pound. Similarly, the removal of the methoxy group in the anthraquinone structure 
of daunorubicin results in the formation of idarubicin, considered to a better 
analog with a broad spectrum of antitumor potential as compared to daunorubicin 
(Figures 1 and 2).
Numerous studies were undertaken in preparation for better analogs. One such 
study was done with the aim of preparing a better daunorubicin analog that was 
prepared and their level of cytotoxicity, DNA damaging property, cellular uptake of 
daunorubicin analogs was investigated to find an anthracycline that can overcome 
drug resistance. Anthracycline derivatives display different action mechanisms in 
causing DNA lesions in various human cancer cell lines as well as in their resistant 
sublines [41]. It was hypothesized that the replacing primary amino group at the C3 
position of the daunosamine moiety by a trisubstituted amidino group might help 
in overcoming drug resistance [41].
Shaul et al. investigated the subcellular localization as well as their cytotoxic 
effect of anthracyclines and their analogs in various cell lines [42]. Association 
between the chemical structure of different anthracyclines and their subcellular 
distribution and their function was investigated in cancer cell lines. Confocal 
microscopy experiments were done to study subcellular localization of anthracy-
clines and their analogs. Fluorescent DNA intercalator displacement experiments 
conducted for studying the intercalative properties demonstrated that the DNA 
intercalation property of anthracycline was not related to their cytotoxic effect. 
Structural information on the binding of anthracycline drugs with the target 
molecule helps in the development of effective drugs.
X-ray crystallographic and NMR (nuclear magnetic resonance) spectroscopic 
studies on anthracyclines-target complex have been conducted in the past and 
provide significant information that helps in the rational designing of drugs. 
Proceeding in similar lines, Yan et al. investigated the interactions of doxorubicin 
and its derivatives with DNA using resonance Raman and surface-enhanced 
resonance Raman scattering spectroscopy and provide significant details on anthra-
cycline binding with DNA [43]. Spectroscopic techniques like Fourier transform 
infrared spectroscopy (FTIR), circular dichroism, fluorescence provided signifi-
cant information binding properties of anthracyclines with nucleic acid [44–48]. 
Conformational studies on anthracycline-nucleic acid complex using computational 
methods like molecular dynamics (MD) simulations also contributes significantly 
to the development of the better anthracycline alternative.
6. Conclusion
Anthracyclines are widely used as antineoplastic agents owing to their great 
anticancer potential. There are several mechanisms proposed by which anthra-
cyclines exert their cytotoxic effect. These drugs mostly act as DNA intercalators 
and halt vital functions like transcription and replication of cells. DNA damage 
by topoisomerase II poisoning, oxidative stress, and by forming anthracycline-
DNA adduct are other proposed mechanism of anthracycline action. Despite their 
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widespread usage in cancer treatment, their administration consequences in certain 
adverse side effects including cardiotoxicity that limits their clinical use. Therefore, 
further elucidation of the mechanism by which anthracycline drugs exert their 
cytotoxic effect becomes extremely important. Structural, in silico molecular 
docking/MD simulations studies and their correlation with the cytotoxic effect 
provide significant information for the development of structure-based analogs. 
The synthesis of novel structure-based anthracycline analogs should be continued 
to get an analog with better efficacy and minimum side effects. The development 
of an analog that can reverse the effect of drug resistance as well as reduce dose-
dependent toxicity is essential.
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